核醫學用放射性同位素的全球市場(2022年～2029年)

本報告提供全球核醫學用放射性同位素市場相關調查分析，提供市場動態，產業分析，市場分析，競爭情形等系統性資訊。

目錄

第1章 全球核醫學用放射性同位素的調查手法和範圍

• 調查手法
• 調查的目的和調查範圍

第2章 全球核醫學用放射性同位素市場-市場定義和概要

第3章 全球核醫學用放射性同位素市場-摘要整理

• 市場明細:各放射性同位素類型
• 市場明細:各應用領域
• 市場明細:各終端用戶
• 市場明細:各地區

第4章 全球核醫學用放射性同位素市場-市場動態

• 影響市場的要素
  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析

第5章 全球核醫學用放射性同位素市場-產業分析

• 波特的五力分析
• 供應鏈分析
• 價格分析
• 法規分析
• PEST分析

第6章 全球核醫學用放射性同位素市場-COVID-19分析

• 市場COVID-19分析
  • COVID-19前的市場方案
  • 目前COVID-19市場方案
  • COVID-19後的市場方案/未來市場方案
• COVID-19的價格的動態
• 需求與供給的頻譜
• 政府在COVID-19疫情下的市場相關措施
• 製造商策略性舉措
• 結論

第7章 全球核醫學用放射性同位素市場:各放射性同位素類型

• 簡介
  • 市場規模分析，及與前一年同期比較成長分析(%):各放射性同位素類型
  • 市場魅力指數:各放射性同位素類型
• 氟-18*
  • 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
• Technetium-99m(Tc-99m)
• 鉈-201(Tl-201)
• 碘(I-123)
• 銣-82(Rb-82)
• 碘-131(I-131)
• 鎦-177(Lu-177)
• 鐳-223(Ra-223)及Alpharadin
• 錒225(Ac-225)
• 其他

第8章 全球核醫學用放射性同位素市場:各應用領域

• 簡介
  • 市場規模分析，及與前一年同期比較成長分析(%):各應用領域
  • 市場魅力指數:各應用領域
• 心臟病*
  • 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
• 腫瘤
• 甲狀腺疾病
• 神經疾病
• 其他

第9章 全球核醫學用放射性同位素市場:各終端用戶

• 簡介
  • 市場規模分析，及與前一年同期比較成長分析(%):各終端用戶
  • 市場魅力指數:各終端用戶
• 醫院*
  • 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
• 診斷中心
• 專門診所
• 教育機關·研究機關
• 其他

第10章 全球核醫學用放射性同位素市場:各地區

• 簡介
  • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年):各地區
  • 市場魅力指數:各地區
• 北美
• 歐洲
• 南美
• 亞太地區
• 中東和非洲

第11章 全球核醫學用放射性同位素市場-競爭情形

• 競爭模式
• 主要的開發與策略
• 企業佔有率分析
• 產品的基準
• 值得注意的主要企業
• 顛覆性技術的企業

第12章 全球核醫學用放射性同位素市場-企業簡介概要

• Cardinal Health, Inc*
  • 企業概要
  • 產品系列及說明
  • 主要亮點
  • 財務概要
• NTP Radioisotopes SOC Ltd
• Nordion Inc.,(Sotera Health company)
• Bayer AG
• GE Company(GE Healthcare)
• NorthStar Medical Radioisotopes, LLC

第13章 全球核醫學用放射性同位素市場-DataM

• 附錄
• 關於本公司·服務
• 諮詢方式

Market Overview

The global nuclear medicine radioisotopes market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Medical radioisotopes are defined as safe radioactive substances that are primarily used to diagnose medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt since the rays can decay as soon as the imaging is completed.

Market Dynamics

The global nuclear medicine radioisotopes market growth is driven by the rising nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.

Increasing SPECT and PET applications is expected to hold the largest share in this market segment

The increase in the global incidence of cancer and modern healthcare facilities have been major drivers for the market's growth. For instance, according to GLOBOCAN 2020, globally, there were 1,92,92,789 new cancer cases in 2020, and it is projected to increase to 2,88,87,940 cases by 2040. Moreover, the increasing SPECT and PET applications contribute to the market's growth. For instance, in February 2022, Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, revealed the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). Furthermore, in December 2021, GE Healthcare launched its most advanced SPECT/CT, a nuclear medicine system, at RSNA21. Such developments are anticipated to boost the development of radioisotopes, thereby contributing to market growth.

Short half-life of radiopharmaceuticals is likely to restrain the market growth

The expiry of a radiopharmaceutical majorly depends on the half-life of the radioisotope and the content of the radionuclide. For example, the radioactivity of F-18 in PET scans decreases if not used within 110 minutes, while the radioactivity of C-11 decreases within 20 minutes. In SPECT diagnosis, the radioactivity of Tc-99m is reduced after six hours, while I-123 and In-111 isotopes should be utilized within 13 and 67 hours, respectively. The non-utilization of radioisotopes within the prescribed shelf life causes radiation and chemical decomposition, reducing radiochemical purity to an unacceptable form, which may prove fatal during diagnosis and therapy.

COVID-19 Impact Analysis

The COVID-19 pandemic has placed significant challenges on healthcare systems, whether in the preparation, response, or recovery phase of the pandemic. This has been primarily managed by dramatically reducing in-and outpatient services for diseases and implementing infection prevention and control measures. For instance, as per a September 2020 published article, titled, "Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020," both diagnostic and therapeutic nuclear medicine procedures declined precipitously to a similar degree, within countries worldwide being affected by the pandemic. As per the same source, countries such as South Korea and Singapore reported a less pronounced impact on nuclear medicine services. However, the overall study results showed that nuclear medicine services worldwide have had an adverse impact on the procedures. In relation to staff health, 15% of respondents experienced COVID-19 infections within their departments. According to an article titled "The Impact of COVID-19 on Nuclear Medicine Operations Including Cardiovascular Manifestations in the USA" published in ScienceDirect Journal, in June 2021, the number of nuclear studies, nuclear cardiac imaging, and oncology PET/CT decreased in March and April 2020 due to the rise of COVID-19 cases and deaths as reported by the Centers for Disease Control and Prevention (CDC). The study further stated that procedures increased from June 2020 to February 2021 as the COVID-19 cases observed a decline.

Segment Analysis

The cardiology segment is expected to hold the largest share in this market segment

The cardiology segment is expected to hold a major market share over the forecast period by application. The major factors attributing to the growth of this segment include the rise in the prevalence of cardiovascular disorders and the surge in applications of SPECT in diagnosing cardiac issues. Cardiovascular disorders include coronary artery disease (CAD), strokes, and atrial fibrillation, necessitating an efficient diagnosis through SPECT.

For instance, according to a study published by the British Heart Foundation in July 2020, approximately 7.5 million people with heart disease in the United Kingdom and nearly 170,000 deaths each year, an average of 460 people each day, or one death every three minutes. Thus, diagnosing CVD at the earlier stages is predicted to bolster the demand for nuclear medicine, ultimately boosting radioisotopes among the patient population.

In addition, several market players are engaged in implementing strategic initiatives, thereby contributing to market growth. For instance, in September 2020, Siemens Healthineers introduced a new version of its c.cam dedicated cardiac nuclear medicine system to the United States market. Such developments are anticipated to fuel the development of radioisotopes in cardiac nuclear medicine, thereby contributing to segment growth.

Geographical Analysis

North America region holds the largest market share of global nuclear medicine radioisotopes market

Within North America, the United States has held the major share of the market. Nuclear medicine in the United States is considered to be gaining pace due to the advancements in technology, including hybrid imaging, the introduction of new radioisotopes for diagnosis, the development of imaging techniques, and the presence of key market players.

The increasing burden of chronic diseases is further contributing to market growth. For instance, as per 2021 Alzheimer's Disease Facts and Figures, an estimated 6.2 million Americans age 65 and older will be living with Alzheimer's dementia in 2021 in the United States. As nuclear medicine techniques play an essential role in the clinical diagnosis of individuals with cognitive impairment, the demand for nuclear medicine radioisotopes is expected to increase with the growing burden of chronic diseases.

The market players adopt various product launches, collaborations, partnerships, mergers, and acquisitions to increase market share. For instance, in August 2021, Curium submitted an investigational new drug application to the United States Food and Drug Administration for a radiopharmaceutical Cu-64 PSMA I&T. It is used in PET in localizing and detecting metastatic prostate cancer. Such developments are expected to fuel the market growth within the region.

Competitive Landscape

The global nuclear medicine radioisotopes market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include NTP Radioisotopes SOC Ltd, Nordion Inc., (Sotera Health company), Cardinal Health, Inc, Bayer AG, GE Company (GE Healthcare) and NorthStar Medical Radioisotopes, LLC. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, in October 2021, the NorthStar Medical Radioisotopes expansion event unveiled advanced radioisotope production equipment and breaks ground on the first-in-kind therapeutic radioisotope production facility.

Global Nuclear Medicine Radioisotopes Market - Key Companies to Watch

Cardinal Health, Inc

Overview: Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States. Its headquarters are in Dublin, Ohio and Dublin, Ireland.

Product Portfolio: It offers an extensive portfolio of PET radiopharmaceuticals dispensed from more than 100 nuclear pharmacies across the country. Some includes Fluorine F 18 flutemetamol (VIZAMYL), Fluorine F 18 fludeoxyglucose, Fluorine F 18 sodium fluoride, Gallium Ga 68 dotatate (Netspot), Nitrogen N 13 ammonia, Copper Cu 64 dotatate (Detectnet).

Why Purchase the Report?

Visualize the composition of the nuclear medicine radioisotopes market segmentation by type of radioisotopes, application, end-user and region highlighting the key commercial assets and players.

Identify commercial opportunities in nuclear medicine radioisotopes market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of nuclear medicine radioisotopes market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players.

The global nuclear medicine radioisotopes market report would provide an access to an approx. 46 market data table, 56 figures and 200 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Nuclear Medicine Radioisotopes Market - By Type of Radioisotopes

Technetium-99m (Tc-99m)

Thallium-201 (Tl-201)

Iodine (I-123)

Fluorine-18

Rubidium-82 (Rb-82)

Iodine-131 (I-131)

Lutetium-177 (Lu-177)

Radium-223 (Ra-223) and Alpharadin

Actinium-225 (Ac-225)

Other Types of Radioisotopes

Global Nuclear Medicine Radioisotopes Market - By Application

Oncology

Cardiology

Thyroid

Neurology

Other Applications

Global Nuclear Medicine Radioisotopes Market - By End-User

Hospitals

Diagnostic centers

Specialty Clinics

Education and Research institutes

Others

Global Nuclear Medicine Radioisotopes Market - By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Nuclear Medicine Radioisotopes Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Nuclear Medicine Radioisotopes Market - Market Definition and Overview

3. Global Nuclear Medicine Radioisotopes Market - Executive Summary

• 3.1. Market Snippet by Type of Radioisotopes
• 3.2. Market Snippet by Application
• 3.3. Market Snippet by End-User
• 3.4. Market Snippet by Region

4. Global Nuclear Medicine Radioisotopes Market - Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Increasing SPECT and PET applications
  • 4.1.2. Restraints:
    • 4.1.2.1. Short half-life of radiopharmaceuticals
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Nuclear Medicine Radioisotopes Market - Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. PEST Analysis

6. Global Nuclear Medicine Radioisotopes Market - COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Nuclear Medicine Radioisotopes Market - By Type of Radioisotopes

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of radioisotopes
  • 7.1.2. Market Attractiveness Index, By Type of radioisotopes
• 7.2. Fluorine-18*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Technetium-99m (Tc-99m)
• 7.4. Thallium-201 (Tl-201)
• 7.5. Iodine (I-123)
• 7.6. Rubidium-82 (Rb-82)
• 7.7. Iodine-131 (I-131)
• 7.8. Lutetium-177 (Lu-177)
• 7.9. Radium-223 (Ra-223) and Alpharadin
• 7.10. Actinium-225 (Ac-225)
• 7.11. Other Types of Radioisotopes

8. Global Nuclear Medicine Radioisotopes Market - By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiology*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Oncology
• 8.4. Thyroid
• 8.5. Neurology
• 8.6. Other Applications

9. Global Nuclear Medicine Radioisotopes Market - By End-user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
  • 9.1.2. Market Attractiveness Index, By End-user
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Diagnostic centers
• 9.4. Specialty Clinics
• 9.5. Education and Research institutes
• 9.6. Others

10. Global Nuclear Medicine Radioisotopes Market - By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of radioisotopes
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of radioisotopes
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of radioisotopes
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of radioisotopes
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of radioisotopes
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Nuclear Medicine Radioisotopes Market - Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Key Developments and Strategies
• 11.3. Company Share Analysis
• 11.4. Product Benchmarking
• 11.5. Key Companies to Watch
• 11.6. Company with disruptive technology

12. Global Nuclear Medicine Radioisotopes Market- Company Profiles

• 12.1. Cardinal Health, Inc*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. NTP Radioisotopes SOC Ltd
• 12.3. Nordion Inc., (Sotera Health company)
• 12.4. Bayer AG
• 12.5. GE Company (GE Healthcare)
• 12.6. NorthStar Medical Radioisotopes, LLC

LIST NOT EXHAUSTIVE

13. Global Nuclear Medicine Radioisotopes Market - DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us